WO2007022193A2 - Process for the preparation of copolymer-1 - Google Patents
Process for the preparation of copolymer-1 Download PDFInfo
- Publication number
- WO2007022193A2 WO2007022193A2 PCT/US2006/031860 US2006031860W WO2007022193A2 WO 2007022193 A2 WO2007022193 A2 WO 2007022193A2 US 2006031860 W US2006031860 W US 2006031860W WO 2007022193 A2 WO2007022193 A2 WO 2007022193A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- copolymer
- initiator
- tyrosine
- lysine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 15
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 14
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 13
- 235000004279 alanine Nutrition 0.000 claims abstract description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 7
- 239000004472 Lysine Substances 0.000 claims abstract description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 5
- 239000004220 glutamic acid Substances 0.000 claims abstract description 5
- 235000018977 lysine Nutrition 0.000 claims abstract description 3
- 229920001184 polypeptide Polymers 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 3
- 235000002374 tyrosine Nutrition 0.000 claims abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 60
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 28
- 229960000583 acetic acid Drugs 0.000 claims description 20
- 239000003999 initiator Substances 0.000 claims description 20
- -1 4-methoxybenzyloxycarbonyl group Chemical group 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 11
- 229920005654 Sephadex Polymers 0.000 claims description 10
- 239000012507 Sephadex™ Substances 0.000 claims description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000012362 glacial acetic acid Substances 0.000 claims description 6
- SNZIFNXFAFKRKT-NSHDSACASA-N (2s)-2-azaniumyl-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoate Chemical compound CC(C)(C)OC1=CC=C(C[C@H]([NH3+])C([O-])=O)C=C1 SNZIFNXFAFKRKT-NSHDSACASA-N 0.000 claims description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 5
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical group [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical group 0.000 claims description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 4
- KAFHLONDOVSENM-HNNXBMFYSA-N O-Benzyl-L-tyrosine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OCC1=CC=CC=C1 KAFHLONDOVSENM-HNNXBMFYSA-N 0.000 claims description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 3
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical group 0.000 claims description 3
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 claims description 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims description 2
- 101100242814 Caenorhabditis elegans parg-1 gene Proteins 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 229940117803 phenethylamine Drugs 0.000 claims description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 2
- ATCFYQUZTYQTJN-AXDSSHIGSA-N (2s)-2-amino-4-benzylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)CC1=CC=CC=C1 ATCFYQUZTYQTJN-AXDSSHIGSA-N 0.000 claims 2
- OWSNAXGBYMMIQQ-GDVGLLTNSA-N (2s)-2-amino-4-tert-butylpentanedioic acid Chemical compound CC(C)(C)C(C(O)=O)C[C@H](N)C(O)=O OWSNAXGBYMMIQQ-GDVGLLTNSA-N 0.000 claims 2
- 238000010511 deprotection reaction Methods 0.000 claims 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical group C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000000962 organic group Chemical group 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000007079 thiolysis reaction Methods 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 150000001242 acetic acid derivatives Chemical class 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000007334 copolymerization reaction Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229910004373 HOAc Inorganic materials 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010072051 Glatiramer Acetate Proteins 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- 229940038717 copaxone Drugs 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- DTETYCNJKAUROO-UHFFFAOYSA-N 4-methyl-1,3-oxazolidine-2,5-dione Chemical compound CC1NC(=O)OC1=O DTETYCNJKAUROO-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000010959 commercial synthesis reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F283/00—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to an improved process for the preparation of copolymer-1.
- the structural formula is: Poly [L-AIa", L-Glu x , L-Lys ⁇ , L- Tyr z ] • n (CH 3 CO 2 H) , wherein w, x, y, z is between 0 with 1.
- the copolymer-1 has a molar ratio of L-AIa : L-GIu : L-Lys : L-Tyr approximately 0.427: 0.150: 0.327 : 0.100, and the deviation may vary by about ⁇ 10%.
- Copolymer-1 is used in immunotherapy for multiple sclerosis.
- the deblocking of the ⁇ -carboxyl group of the glutamic acid is effected by hydrogen bromide in glacial acetic acid and is followed by the removal of the trifluoroacetyl groups from the lysine residues by 1 M piperidine .
- the method consists of copolymerization of N-Carboxyanhydride (NCA) of alanine (AIa-NCA), ⁇ -benzyl glutamate [GIu(OBzI)-NCA], ⁇ -N- Benzyloxycarbonyl lysine [Lys (Z) -NCA] and O-benzyl tyrosine [Tyr (BzI) -NCA] in an inert solvent with a initiator.
- the choice of Tyr (BzI) -NCA provides the advantage of being stable, crystalline and easy to obtain in high purity.
- the copolymerization involving the four amino acid NCAs and diethylamine offers copolymer-1 with reproducible amino acids composition and molecular weight distribution.
- copolymer-1 HBr salt was treated with sodium carbonate to pH 8-9 then acidify to pH 3-4 by acetic acid to convert the HBr salt to copolymer-1 acetic acid salt.
- Copolymer-1 acetic acid salt can be further purified by Sephadex G50 eluting with IN acetic acid to collect the copolymer-1 acetic salt with the desired molecular weight range. Good yields of copolymer-1 acetic acid salt can be obtained in such a manner.
- the method consists of copolymerization of N-Carboxyanhydride of alanine (Ala-NCA) , ⁇ -t-butyl glutamate [GIu (OBut) -NCA] , ⁇ -N-t-butyloxycarbonyl lysine [Lys (Boc) -NCA] and O-t- butyl tyrosine [Tyr (But) -NCA] in an inert solvent with a initiator.
- the copolymerization involving the four amino acid NCAs and diethylaitiine offers copolymer-1 with reproducible amino acids composition and molecular weight distribution.
- copolymer-1 HCl salt was treated with sodium carbonate to pH 8-9 then acidified to pH 3-4 by acetic acid to convert the HBr salt to copolymer-1 acetic acid salt.
- Copolymer-1 acetic acid salt can be further purified by Sephadex G50 eluting with IN acetic acid to collect the copolymer-1 acetic salt with the desired molecular weight range. Good yields of copolymer-1 acetic acid salt can be obtained in such a manner.
- the hydrogen chloride in glacial acetic acid can be replaced with trifluoroacetic acid, hydrogen chloride in dioxane or ethyl acetate [0008]
- All the amino acid NCAs can be prepared by reaction of the corresponding N-butyloxycarbonyl-amino acid with triphosgene and triethylamine in a solvent medium [J. Org. Chem. 1992, 57, 2755-2756] .
- Ala-NCA, GIu(OBzI)-NCA, Lys(Z)-NCA and Tyr (BzI) -NCA can be also prepared by reaction of the corresponding N-unprotected amino acid with phosgene, diphosgene or triphosgene [Tetrahedron Letters 1988, 29, 5859-5862] . [0009] In point of fact, the reaction conditions of amino acid NCAs synthesis are similar. In order to reduce the production cost of copolymer-1, it is possible to use a mixture of alanine, ⁇ -benzyl glutamate, ⁇ -N-Benzyloxycarbonyl lysine and 0-benzyl tyrosine as starting compounds instead of the amino acid NCAs.
- the amino acids mixture can be converted to the corresponding amino acid NCAs mixture by the same reaction.
- the amino acid NCAs can be converted to copolymer-1 in the subsequent copolymerization.
- the mixture of alanine, ⁇ -t-butyl glutamate, ⁇ -Nt-butyloxycarbonyl lysine and O- t-butyl tyrosine can also be used as starting compounds directly.
- the polymerization of NCAs can be carried out by simply mixing the above four NCAs in a solvent such as dioxane, tetrahydrofuran, dichloromethane, dimethylformamide, N-methylpyrrolidone, sulfolane, nitrobenzene, tetramethylurea, dimethylsulfone or other inert solvents that are capable of dissolving NCAs and results in a homogeneous reaction.
- a solvent such as dioxane, tetrahydrofuran, dichloromethane, dimethylformamide, N-methylpyrrolidone, sulfolane, nitrobenzene, tetramethylurea, dimethylsulfone or other inert solvents that are capable of dissolving NCAs and results in a homogeneous reaction.
- the reaction was initiated by addition of an initiator solution.
- Organic amine is a preferred initiator.
- the molar ratio of initiator to total NCA used is in the range of 0.7% to 5%.
- the reaction can be carried out at any convenient temperature but temperatures between 0-50 0 C are preferred.
- Other initiators include sodium methoxide, sodium t-butoxide, hexylamine, phenethylamine or transition metal initiator such as bbyNi (COD) , (Pme3)4Co.
- Fig. 1 shows the elution profile of copolymer- 1 HBr that has passed through a Sephadex G25 column.
- Fig. 2 shows the elution profile of copolymer- 1 acetate that has passed through a Sephadex G-50 column .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Polyamides (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06801544A EP1922345A4 (en) | 2005-08-15 | 2006-08-15 | Process for the preparation of copolymer-1 |
CA002619123A CA2619123A1 (en) | 2005-08-15 | 2006-08-15 | Process for the preparation of copolymer-1 |
AU2006279557A AU2006279557A1 (en) | 2005-08-15 | 2006-08-15 | Process for the preparation of copolymer-1 |
JP2008527066A JP2009504885A (en) | 2005-08-15 | 2006-08-15 | Method for producing copolymer-1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70821805P | 2005-08-15 | 2005-08-15 | |
US60/708,218 | 2005-08-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007022193A2 true WO2007022193A2 (en) | 2007-02-22 |
WO2007022193A3 WO2007022193A3 (en) | 2007-05-31 |
WO2007022193B1 WO2007022193B1 (en) | 2007-07-19 |
Family
ID=37758310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/031860 WO2007022193A2 (en) | 2005-08-15 | 2006-08-15 | Process for the preparation of copolymer-1 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070141663A1 (en) |
EP (1) | EP1922345A4 (en) |
JP (1) | JP2009504885A (en) |
KR (1) | KR20080048482A (en) |
CN (1) | CN101243113A (en) |
AU (1) | AU2006279557A1 (en) |
CA (1) | CA2619123A1 (en) |
WO (1) | WO2007022193A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009016643A1 (en) * | 2007-07-31 | 2009-02-05 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
WO2010115175A1 (en) | 2009-04-03 | 2010-10-07 | Momenta Pharmaceticals, Inc. | Control of copolymer compositions |
WO2010140157A1 (en) * | 2009-06-04 | 2010-12-09 | Council Of Scientific & Industrial Research | Aprocess for the preparation of copolymer - 1 (cop-i), composed of l-alanine, l-lysine, l-glutamic acid and l-tyrosine-drug for the treatment of multiple sclerosis |
GB2478837A (en) * | 2011-03-14 | 2011-09-21 | Cipla Ltd | Preparation of glatiramer |
WO2011139752A3 (en) * | 2010-04-27 | 2012-04-05 | Dr. Reddy's Laboratories Ltd. | Preparation of polypeptides and salts thereof |
US8399600B2 (en) | 2008-08-07 | 2013-03-19 | Sigma-Aldrich Co. Llc | Preparation of low molecular weight polylysine and polyornithine in high yield |
US8753833B2 (en) | 2007-06-21 | 2014-06-17 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
US9395374B2 (en) | 2008-04-16 | 2016-07-19 | Momenta Pharmaceuticals, Inc. | Analysis of amino acid copolymer compositions |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007269140A1 (en) * | 2006-07-05 | 2008-01-10 | Momenta Pharmaceuticals, Inc. | Improved process for the preparation of copolymer-1 |
WO2010017292A1 (en) * | 2008-08-07 | 2010-02-11 | Scinopharm Taiwan, Ltd. | Synthesis of glatiramer acetate |
BR112012011783A2 (en) * | 2009-11-17 | 2019-09-24 | Ares Trading Sa | "Methods for enhancing the design, bioavailability and efficiency of random sequence polymer compositions via whey protein detection of random sequence polymer compositions." |
EP2523668A1 (en) | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
CN103980494B (en) * | 2014-04-21 | 2016-04-13 | 国家纳米科学中心 | A kind of polypeptide polymer with anti-tumor activity and its preparation method and application |
CN104844697B (en) * | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | The preparation method of acetic acid copaxone |
CN108047071B (en) * | 2017-12-07 | 2020-07-28 | 杭州同舟生物技术有限公司 | Carcinone artificial hapten, artificial antigen, preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
CZ290975B6 (en) * | 1998-06-05 | 2002-11-13 | Ústav Makromolekulární Chemie Av Čr | Functionalized polymers of alpha-amino acids and process of their preparation |
CA2411786C (en) * | 2002-11-13 | 2009-01-27 | Brantford Chemicals Inc. | A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids |
-
2006
- 2006-08-15 CA CA002619123A patent/CA2619123A1/en not_active Abandoned
- 2006-08-15 US US11/504,793 patent/US20070141663A1/en not_active Abandoned
- 2006-08-15 EP EP06801544A patent/EP1922345A4/en not_active Withdrawn
- 2006-08-15 WO PCT/US2006/031860 patent/WO2007022193A2/en active Application Filing
- 2006-08-15 KR KR1020087006405A patent/KR20080048482A/en not_active Application Discontinuation
- 2006-08-15 JP JP2008527066A patent/JP2009504885A/en active Pending
- 2006-08-15 AU AU2006279557A patent/AU2006279557A1/en not_active Abandoned
- 2006-08-15 CN CNA2006800298599A patent/CN101243113A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of EP1922345A4 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8753833B2 (en) | 2007-06-21 | 2014-06-17 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
WO2009016643A1 (en) * | 2007-07-31 | 2009-02-05 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
US8993722B2 (en) | 2007-07-31 | 2015-03-31 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
US10160992B2 (en) | 2008-04-16 | 2018-12-25 | Momenta Pharmaceuticals, Inc. | Analysis of amino acid copolymer compositions |
US9410964B2 (en) | 2008-04-16 | 2016-08-09 | Momenta Pharmaceuticals, Inc. | Analysis of amino acid copolymer compositions |
US9395374B2 (en) | 2008-04-16 | 2016-07-19 | Momenta Pharmaceuticals, Inc. | Analysis of amino acid copolymer compositions |
US8399600B2 (en) | 2008-08-07 | 2013-03-19 | Sigma-Aldrich Co. Llc | Preparation of low molecular weight polylysine and polyornithine in high yield |
US8859489B2 (en) | 2009-04-03 | 2014-10-14 | Momenta Pharmaceuticals, Inc. | Water-mediated control of depolymerization step of glatiramer acetate synthesis |
US8058235B1 (en) | 2009-04-03 | 2011-11-15 | Momenta Pharmaceuticals, Inc. | Water-mediated control of depolymerization step of glatiramer acetate synthesis |
WO2010115175A1 (en) | 2009-04-03 | 2010-10-07 | Momenta Pharmaceticals, Inc. | Control of copolymer compositions |
US9150609B2 (en) | 2009-06-04 | 2015-10-06 | Council Of Scientific & Industrial Research | Process for the preparation of copolymer-1 using a polymer supported dialkylamine initiator |
WO2010140157A1 (en) * | 2009-06-04 | 2010-12-09 | Council Of Scientific & Industrial Research | Aprocess for the preparation of copolymer - 1 (cop-i), composed of l-alanine, l-lysine, l-glutamic acid and l-tyrosine-drug for the treatment of multiple sclerosis |
WO2011139752A3 (en) * | 2010-04-27 | 2012-04-05 | Dr. Reddy's Laboratories Ltd. | Preparation of polypeptides and salts thereof |
GB2478837A (en) * | 2011-03-14 | 2011-09-21 | Cipla Ltd | Preparation of glatiramer |
Also Published As
Publication number | Publication date |
---|---|
AU2006279557A1 (en) | 2007-02-22 |
EP1922345A2 (en) | 2008-05-21 |
WO2007022193A3 (en) | 2007-05-31 |
CN101243113A (en) | 2008-08-13 |
CA2619123A1 (en) | 2007-02-22 |
KR20080048482A (en) | 2008-06-02 |
JP2009504885A (en) | 2009-02-05 |
WO2007022193B1 (en) | 2007-07-19 |
US20070141663A1 (en) | 2007-06-21 |
EP1922345A4 (en) | 2009-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1922345A2 (en) | Process for the preparation of copolymer-1 | |
FI90780B (en) | synthetic resin | |
US4594409A (en) | Producing sequential polyamino acid resin | |
CN110606947B (en) | Method for rapid ring-opening polymerization of N-carboxyanhydride initiated by strong base | |
Katakai et al. | Polydepsipeptides. 9. Synthesis of sequential polymers containing some amino acids having polar side chains and (S)-lactic acid | |
NO166532B (en) | PROCEDURE FOR PREPARING THE PEPTID H-ARG-X-Z-Y-TYR-R. | |
SU1082319A3 (en) | Process for preparing tetrapeptides or their acid addition salts | |
US20090035816A1 (en) | Process for the preparation of a polypeptide | |
Aldrian‐Herrada et al. | Solid‐phase synthesis of peptide nucleic acid (PNA) monomers and their oligomerization using disulphide anchoring linkers | |
Parkhe et al. | Determination of the chain-folding pattern in the crystalline domains of the repetitive polypeptide {(AlaGly) 3GluGly (GlyAla) 3GluGly} 10 by FTIR studies of its blends with a carbon-13 enriched analog | |
AU705716B2 (en) | Nalpha-2-(4-nitrophenulsulfonyl)ethoxycarbonyl-amino acids | |
KR20220038320A (en) | preparing methods of PNA oligomers on solution phase | |
FI88031C (en) | 4- (SUBSTITUTES AMINOCARBONYLOXIMETHYL) PHENOXYETHYXRADERATED, FOERFARANDE FOER FRAMSTAELLNING AV DESSA OCH DERAS ANVAENDNING I EN FASTFASSYNTES AV PEPTID-AMINOALKYLAMIDER | |
US4764595A (en) | Resin support for solid phase peptide synthesis | |
Dessipri et al. | Trifluoroalanine N-carboxy anhydride: a reactive intermediate for the synthesis of low surface energy polypeptides | |
AU2004262570A1 (en) | Preparation of somatostatin peptides | |
Fukushima | Secondary structural analysis in the solid state for analogous sequential polypeptides of glycine-rich sequence of spider dragline silk | |
US4525576A (en) | Process for producing sequential polyamino acid resin | |
JP5286822B2 (en) | Process for producing polyamino acid or polyamino acid copolymer | |
Takahashi | Solid-phase syntheses of Glu20Ala20Phe and Ala20Glu20Phe by the step-by-step coupling of dipeptide and tetrapeptide. | |
Ueyanagi et al. | Asymmetric synthesis catalyzed by oligo ((S)‐alanine) | |
Omura et al. | Synthesis and characterization of poly (ε-carbobenzoxy-l-lysyl-γ-benzyl-l-glutamate) | |
Takeuchi et al. | Synthesis and Conformational Behaviors of Unnatural Peptides Alternating Chiral and Achiral α, α‐Disubstituted α‐Amino Acid Units | |
JP3418693B2 (en) | D-galactopyranosyl-gluconic acid derivatives of poly-ε-substituted-L-lysine | |
Mazzier | Functionalized short peptides and polypeptides: from organic reactions, through secondary structure control, to supramolecular applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680029859.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008527066 Country of ref document: JP Ref document number: 2006279557 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 565911 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2619123 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 672/KOLNP/2008 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006279557 Country of ref document: AU Date of ref document: 20060815 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006801544 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: KR |